Natural killer cells: From bench to cancer therapy

Expert Opinion on Biological Therapy

Volumn 6, Issue 10, 2006, Pages 967-970

  Boyiadzis, Michael ^a   Foon, Kenneth A ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b NONE

Author keywords

Cancer; Clinical trials; Immunotherapy; Natural killer cells

Indexed keywords

CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; NATURAL KILLER CELL RECEPTOR; RITUXIMAB; TRASTUZUMAB;

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER; CELL ACTIVATION; CLINICAL RESEARCH; CYTOKINE RELEASE; CYTOTOXICITY; EXPERIMENTAL MODEL; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INNATE IMMUNITY; LYMPHOMA; NATURAL KILLER CELL; NONHUMAN; REVIEW; STEM CELL TRANSPLANTATION;

ANIMALS; CANCER VACCINES; CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL;

EID: 33749333768     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.10.967     Document Type: Review

References (24)

1. HERBERMAN RB, NUNN ME, LAVRIN DH: Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int. J. Cancer (1975) 16(2):216-229.
2. ROSENBERG EB, HERBERMAN RB, LEVINE PH et al.: Lymphocyte cytotoxicity reactions to leukemia-associated antigens in identical twins. Int. J. Cancer (1972) 9(3):648-658.
3. WHITESIDE TL: Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin. Cancer Biol. (2006) 16(1):3-15.
4. ROSENBERG SA, LOTZE MT, MUUL LM et al.: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. (1985) 313(23):1485-1492.
5. ROSENBERG SA, LOTZE MT, YANG JC et al.: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. (1989) 210(4):474-484; discussion 484-475.
6. CARSON WE, FEHNIGER TA, HALDAR S et al.: A potential role for interleukin-15 in the regulation of human natural killer cell survival. J. Clin. Invest. (1997) 99(5):937-943.
7. COOPER MA, BUSH JE, FEHNIGER TA et al.: In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood (2002) 100(10):3633-3638.
8. RANSON T, VOSSHENRICH CA, CORCUFF E et al.: IL-15 is an essential mediator of peripheral NK-cell homeostasis. Blood (2003) 101(12):4887-4893.
9. RUGGERI L, CAPANNI M, CASUCCI M et al.: Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood (1999)94(1):333-339.
10. RUGGERI L, CAPANNIM, URBANI F. et al.: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (2002) 295(5562):2097-2100.
11. GIEBEL S, LOCATELLI F, LAMPARELLI T et al.: Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood (2003) 102(3):814-819.
12. HSU KC, KEEVER-TAYLOR CA, WILTON A et al.: Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood (2005) 105(12):4878-4884.
13. MILLER JS, SOIGNIER Y, PANOSKALTSIS-MORTARI A et al.: Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood (2005) 105(8):3051-3057.
14. CLYNES RA, TOWERS TL, PRESTA LG, RAVETCH JV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. (2000) 6(4):443-446.
15. ANSELL SM, WITZIG TE, KURTIN PJ et al.: Phase I study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood (2002) 99(1):67-74.
16. CARSON WE, PARIHAR R, LINDEMANN MJ et al.: Interleukin-2 enhances the natural killer cell response to Hercepcin-coated Her2/neu-positive breast cancer cells. Eur. J. Immunol. (2001) 31(10):3016-3025.
17. FRIEDBERG JW NEUBERG D, GRIBBEN JG et al.: Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br. J. Haematol. (2002) 117(4):828-834.
18. PARIHAR R, NADELLA P, LEWIS A et al.: A Phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients. Clin. Cancer Res. (2004) 10(15):5027-5037.
19. KALINSKI P, MAILLIARD RB, GIERMASZ A et al.: Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin. Biol. Ther. (2005) 5(10):1303-1315.
20. GONG JH, MAKI G, KLINGEMANN HG: Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia (1994) 8(4):652-658.
21. YAN Y, STEINHERZ P, KLINGEMANN HG et al.: Antileukemia activity of a natural killer cell line against human leukemias. Clin. Cancer Res. (1998) 4(11):2859-2868.
22. MAKI G, KLINGEMANN HG, MARTINSON JA, TAM YK: Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. J. Hematother. Stem Cell Res. (2001) 10(3):369-383.
23. ARAI S, KINDY K, SWEARINGEN M et al.: Phase I study of adoptive immunotherapy using the cytotoxic natural killer (NK) cell line, NK-92, for treatment of advanced renal cell carcinoma and malignant melanoma. Blood (2003) 102(11):693A-693A.
24. TONN T, BECKER S, ESSER R, SCHWABE D, SEIFRIED E: Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J. Hematother. Stem Cell Res. (2001) 10(4):535-544.